Moderna says COVID-19 vaccine safe and effective for teens, adolescents; will seek expanded FDA approval

Moderna today said its two-dose COVID-19 vaccine is safe and effective for individuals between 12 and 17 years old, citing data from its ongoing phase 2/3 clinical trial of 3,700 participants. Moderna reported a vaccine efficacy of 93% within 14 days of trial participants’ first dose, with zero reported cases of symptomatic COVID-19 two weeks after their final dose. Moderna said it will submit its data to the Food and Drug Administration in early June as part of a requested expansion of its emergency use authorization to include teens and adolescents.